Botox firms up Allergan revenue

Irish pharmaceutical firm Allergan said continued solid demand for Botox and breast implants drove its revenue up 9pc in the second quarter, ahead of market expectations. Its strong position at the half-year stage caused Allergan to lift its full-year guidance for revenue and margins. Shares in the group rose 0.4pc to $251.03.